FIELD: medicine; pharmaceuticals.
SUBSTANCE: treatment of alcohol use disorder. The use of mavoglurant in patients with alcohol use disorder to reduce alcohol consumption and to promote abstinence from alcohol use is disclosed.
EFFECT: effective reduction of alcohol use and stimulation of abstinence from alcohol use in patients with alcohol use disorder.
12 cl, 4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF MAVOGLURANT TO REDUCE COCAINE INTAKE OR TO PREVENT RECURRENT COCAINE INTAKE | 2018 |
|
RU2804834C2 |
| COMPOSITIONS AND METHODS OF PREVENTING AND TREATING ADDICTIONS | 2008 |
|
RU2492858C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF ADDICTION, MENTAL DISORDERS AND NEURODEGENERATIVE DISEASE | 2011 |
|
RU2674259C2 |
| METHOD FOR RELIEVING ALCOHOL CONSUMPTION SYMPTOMS | 2008 |
|
RU2526157C2 |
| (-)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE, ITS COMPOSITION AND USING AS INHIBITOR OF DOPAMINE REUPTAKE | 2002 |
|
RU2300522C2 |
| TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | 2013 |
|
RU2665134C2 |
| PHARMACEUTICAL COMBINATION FOR TREATMENT OF ALCOHOLIC DEPENDENCE | 2017 |
|
RU2681931C2 |
| USE OF OPIOID RECEPTOR ANTAGONIST WITH K-ACTIVITY AND VORTIOXETINE FOR TREATMENT OF DEPRESSIVE DISORDER WITH MELANCHOLIC FEATURES | 2014 |
|
RU2679661C1 |
| THERAPEUTIC AGENTS | 2008 |
|
RU2468025C2 |
| CYCLOPROPYLPIPERIDINE GLYCINE TRANSPORTER INHIBITORS | 2005 |
|
RU2387644C2 |
